ASP Isotopes Inc. Common Stock Q4 FY2025 earnings call

• Transition from development stage to commercial delivery. - 2026 plan: First commercial shipments of silicon-28, ytterbium-176, carbon-14; radiopharmaceuticals expansion to US; helium and LNG at Virginia Gas Project progressing; Quantum Leap Energy to become independent public company. - Nuclear medicine at intersection of cancer therapies trend and isotope shortage; building Western alternative for utopium-176 and carbon-14. - Electronics building next-gen electronic gases company, silicon-28 key for quantum computing and semiconductors. - Helium and LNG with nameplate capacity expected in 2026 third quarter. - Quantum Leap Energy in S-1 registration process.

Nuclear medicine: 2025 revenue from radiopharmaceuticals grew from $3.9 million in 2024 to $5.7 million in 2025. Utopium-176 plant is producing Ytterbium-176, expecting first commercial shipments in mid-2026 or third quarter. Carbon-14 has signed a take-or-pay contract with a North American customer. Radiopharmacy revenue target for 2026 is $10 million or more. Electronics: Signed three purchase orders for silicon-28, shipped first samples in August 2025, expect to ship first 728 product in second quarter of 2026. Helium and LNG: Virginia Gas Project drilling complete 4 months ahead of schedule, expected to reach nameplate capacity in third quarter of 2026. Quantum Leap Energy: On track to become an independent public company with confidential S-1 submitted.

2026 milestones: First enriched silicon-28 product to ship in second quarter; carbon-14 initial commercial shipments around mid-year; ytterbium-176 initial commercial shipments mid-year or third quarter; helium phase one nameplate capacity in third quarter of 2026; radiopharmacy revenue target $10 million or more in 2026. 2031 EBITDA target: >$300 million, excluding QLE, with electronics $150M-$200M, natural gas $100M-$200M, medical isotopes $40M-$100M, radiopharmaceuticals $40M-$100M.

Supply chains constrained, geographically concentrated, or strategically vulnerable. No credible Western alternative at commercial scale today for relevant markets. Uncertainty in product shipment timing. Market price volatility for helium and isotopes. Uncertainty related to QLE's S-1 registration process.

Q: Quantify 2026 revenue range and EBITDA guidance.

A: Silicon-28 low single digits million, carbon-14 ~$2.5M/year, ytterbium-176 ~$20M/year, LNG ~$12M/year, helium revenue varies with price; EBITDA target 2031 excludes QLE.

Q: Thoughts on monetizing helium business.

A: Helium market hot, consider market debut listing/spin out.

Q: Silicon-28 customer testing and ytterbium demand.

A: Silicon-28 samples tested successfully, ytterbium price customer-specific, plan to expand capacity to 2 kg.